Compare PLSE & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | STVN |
|---|---|---|
| Founded | 2014 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | 2015 | 2021 |
| Metric | PLSE | STVN |
|---|---|---|
| Price | $52.32 | $15.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $67.67 | $19.46 |
| AVG Volume (30 Days) | 362.6K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 0.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $480.71 | $6.90 |
| Revenue Next Year | $177.98 | $2.38 |
| P/E Ratio | ★ N/A | $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $12.05 |
| 52 Week High | $58.94 | $24.01 |
| Indicator | PLSE | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 42.52 |
| Support Level | $49.66 | $13.12 |
| Resistance Level | $56.54 | $17.19 |
| Average True Range (ATR) | 4.03 | 1.10 |
| MACD | -0.08 | -0.15 |
| Stochastic Oscillator | 24.10 | 42.74 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.